New drug offers hope for lymphoma patients who Can't get transplants
NCT ID NCT06811272
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see how long patients live without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Epcoritamab (a bispecific antibody that helps immune cells attack cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for patients with relapsed/refractory large B-cell lymphoma who cannot undergo a stem cell transplant.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to all patients. Epcoritamab can cause serious side effects like cytokine release syndrome and immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Newton-Wellesley Hospital
RECRUITINGNewton, Massachusetts, 02462, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- Can a single shot build a cancer army inside the body?
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells take aim at Tough-to-Treat blood cancers